The aim of our research is to evaluate the curative effect and safety of CyberKnife stereotactic body radiation therapy in treating small hepatocellular carcinoma (HCC) patients with decompensated cirrhosis.
Primary HCC diagnosed by a surgeon and/or radiologist and oncologist according to the international guidelines for the management of HCC or by pathology
Unfeasible or refusing to undergo other treatments;
Residual normal liver volume ≥700 cc;
With decompensated cirrhosis (Child-Pugh B or C classification);
With Tumor thrombus；
With extrahepatic metastasis;
With lymph node involvement.